AAIC 2026 Plenary Sessions

Migration, Crosslink

📖

AAIC 2026 Plenary Sessions

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-aaic-2026-plenary-sessions

📖 Wiki Page

event1451 wordssynced 2026-04-02

Dates: July 12-15, 2026 Location: ExCeL London, United Kingdom Organizer: [Alzheimer's Association](https://www.alz.org/) Session Times: 11:00 AM - 12:15 PM BST (daily)

Overview

flowchart TD events_aaic_2026_plenary_sessi["AAIC 2026 Plenary Sessions"] style events_aaic_2026_plenary_sessi fill:#4fc3f7,stroke:#333,color:#000 events_aaic_2026_ple_0["Conference Context"] events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_0 style events_aaic_2026_ple_0 fill:#81c784,stroke:#333,color:#000 events_aaic_2026_ple_1["Role of Plenary Sessions at AAIC"] events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_1 style events_aaic_2026_ple_1 fill:#ef5350,stroke:#333,color:#000 events_aaic_2026_ple_2["AAIC 2026 Scientific Themes"] events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_2 style events_aaic_2026_ple_2 fill:#ffd54f,stroke:#333,color:#000 events_aaic_2026_ple_3["Plenary Session Schedule"] events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_3 style events_aaic_2026_ple_3 fill:#ce93d8,stroke:#333,color:#000 events_aaic_2026_ple_4["Sunday, July 12, 2026 Opening Plenary"] events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_4 style events_aaic_2026_ple_4 fill:#4fc3f7,stroke:#333,color:#000 events_aaic_2026_ple_5["Monday, July 13, 2026 Featured Plenary"] events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_5 style events_aaic_2026_ple_5 fill:#81c784,stroke:#333,color:#000

...

Dates: July 12-15, 2026 Location: ExCeL London, United Kingdom Organizer: [Alzheimer's Association](https://www.alz.org/) Session Times: 11:00 AM - 12:15 PM BST (daily)

Overview

Mermaid diagram (expand to render)

The plenary sessions at AAIC 2026 represent the centerpiece of the conference, featuring invited presentations from world-leading researchers on the most significant advances in Alzheimer's disease, dementia, and related neurodegenerative conditions. These sessions provide attendees with comprehensive updates on the state of Alzheimer's research, therapeutic development, and emerging scientific insights that will shape the field's future direction["@aaic2026"].

The plenary program at AAIC 2026 reflects the remarkable transformation in Alzheimer's research over the past decade—from a field with limited therapeutic options to one with multiple disease-modifying therapies approved and numerous programs in clinical development. The sessions synthesize cutting-edge basic science discoveries with clinical translation insights, providing a comprehensive view of where the field stands and where it is heading.

Conference Context

Role of Plenary Sessions at AAIC

Plenary sessions serve multiple critical functions at the Alzheimer's Association International Conference:

Synthesis of Major Advances: Presenters distill complex research into accessible summaries of the most important findings

Cross-Disciplinary Integration: Sessions bring together basic scientists, clinicians, and clinical trialists

Future Directions: Plenary speakers often present unpublished data and discuss emerging hypotheses

Career Development: Junior researchers observe senior investigators presenting landmark findings

Media Attention: Plenary presentations frequently generate media coverage and influence public understanding

AAIC 2026 Scientific Themes

AAIC 2026 plenary sessions focus on several major scientific themes:

Amyloid and Tau Biology: Understanding the relationship between core pathological proteins
Neuroimmune Interactions: Microglial biology and neuroinflammation
Biomarker Evolution: Blood-based biomarkers and their clinical application
Therapeutic Translation: From mechanism to approved therapy
Prevention Strategies: Primary and secondary prevention approaches

Plenary Session Schedule

Sunday, July 12, 2026 — Opening Plenary

Theme: "The State of Alzheimer's Science: Translating Progress into Promise"

The opening plenary session sets the stage for AAIC 2026 by providing an overview of the current state of Alzheimer's research and therapy development. Expected topics include:

Overview of Approved Therapies: Summary of lecanemab and donanemab clinical data
Pipeline Landscape: Review of therapies in clinical development
Biomarker Integration: How biomarkers are transforming clinical trial design
Global Perspectives: Alzheimer's research worldwide

The opening session typically features the Alzheimer's Association Chief Science Officer and prominent clinical researchers.

Monday, July 13, 2026 — Featured Plenary

Theme: "Neuroinflammation and Immune Responses in Alzheimer's Disease"

The Monday plenary focuses on the critical role of neuroinflammation in Alzheimer's disease pathogenesis[@heneka2015]. Expected content includes:

Microglial Biology: Latest understanding of microglial activation states
TREM2 Biology: TREM2 variants and microglial function
Complement System: Role of complement in synaptic pruning
Therapeutic Implications: Anti-inflammatory and immunomodulatory approaches

Tuesday, July 14, 2026 — Keynote Address

Theme: "From Amyloid to Z: Integrating Multiple Mechanisms in Alzheimer's Disease"

The keynote address provides an integrative view of Alzheimer's disease pathogenesis[@scheltens2016]. Topics expected include:

Amyloid Cascade Hypothesis: Current status and modifications
Tau Propagation: Mechanisms of tau spreading
Vascular Contributions: Vascular factors in neurodegeneration
Metabolic Dysfunction: Role of metabolic disease in dementia
Systems Integration: How multiple mechanisms interact

Wednesday, July 15, 2026 — Closing Plenary

Theme: "The Future of Alzheimer's Prevention and Treatment"

The closing plenary looks forward to the future of the field:

Prevention Trials: Updates on primary prevention studies
Combination Therapies: Approaches targeting multiple mechanisms
Precision Medicine: Biomarker-driven patient selection
Global Initiatives: World Health Organization and national dementia plans

Major Scientific Topics

Amyloid and Tau Biology

The relationship between amyloid-beta and tau pathology remains central to Alzheimer's disease research[@battaglia2022]. Plenary presentations are expected to address:

Amyloid Pathology

Oligomer Hypotheses: Evidence for soluble oligomers as the toxic species
Amyloid-Related Imaging Abnormalities (ARIA): Mechanisms and management
Amyloid Clearance: How anti-amyloid therapies work
Amyloid Independence: Evidence for amyloid-independent pathways

Tau Pathology

Tau Spreading: Prion-like propagation mechanisms
Post-Translational Modifications: Phosphorylation, acetylation, truncation
Tau PET: Imaging tau pathology in living patients
Tau-Targeting Therapies: Anti-tau antibodies and small molecules

The NIA-AA Research Framework emphasizes amyloid, tau, and neurodegeneration (AT(N) biomarker categories[@jack2018], and plenary sessions regularly address each component.

Neuroinflammation

Neuroinflammation has emerged as a critical component of Alzheimer's disease pathogenesis[@heneka2015]:

Microglial Biology

Disease-Associated Microglia (DAM): Microglial activation states
TREM2 Variants: Genetic links between microglial function and AD risk
Microglial Dysfunction: How microglial failure contributes to disease
CSF1R Inhibition: Microglial depletion approaches

Neuroimmune Interactions

Complement System: C1q and C3 in synapse elimination
NLRP3 Inflammasome: Inflammatory signaling in neurodegeneration
Astrocyte Reactivity: A1/A2 astrocyte phenotypes
Blood-Brain Barrier: Immune cell trafficking in AD

Biomarkers

Biomarkers have transformed Alzheimer's clinical trials and are expected to feature prominently in plenary sessions:

Fluid Biomarkers

Tau Biomarkers: p-tau217, p-ttau181 in blood
Amyloid Biomarkers: Aβ42/40 ratio in CSF and blood
Neurodegeneration: Neurofilament light chain (NFL)
Astrocytic Markers: GFAP as marker of astrogliosis

Imaging Biomarkers

Amyloid PET: Standardized quantification (Centiloid)
Tau PET: Regional tau and clinical correlation
FDG PET: Metabolic dysfunction patterns
Structural MRI: atrophy measures

The development of blood-based biomarkers is revolutionizing Alzheimer's diagnosis and clinical trial design, enabling earlier detection and more efficient screening.

Therapeutic Translation

With multiple disease-modifying therapies now approved, therapeutic translation is a major plenary focus[@long2023]:

Approved Therapies

Lecanemab: Mechanism, clinical trial results, real-world experience
Donanemab: TRAILBLAZER program data, approved indications

Pipeline Programs

Anti-Amyloid Programs: New antibodies in development
Anti-Tau Approaches: Immunotherapies and small molecules
Neuroprotective Strategies: Synaptic preservation, metabolic support
Combination Approaches: Multi-target strategies

Prevention Strategies

Primary and secondary prevention trials represent the cutting edge of Alzheimer's intervention:

Primary Prevention

DIAN-TU: Prevention in autosomal dominant AD
A4 Study: Anti-amyloid in preclinical AD
Other Prevention Trials: Various approaches in cognitively normal individuals

Secondary Prevention

Leqembi Prevention: Studies in preclinical populations
Lifestyle Interventions: Diet, exercise, cognitive engagement

Plenary Speaker Profiles

Expected Speakers

AAIC 2026 plenary sessions feature internationally recognized leaders in Alzheimer's research:

Academic Leaders: Leading researchers from major universities
Industry Scientists: Chief Scientific Officers from pharmaceutical companies
Clinical Experts: Clinicians with extensive trial experience
Government Representatives: NIH and FDA officials

Speaker Selection

Plenary speakers are selected by the AAIC Scientific Program Committee based on:

Scientific Impact: Discovery of major importance
Field Representation: Balanced representation across research areas
Diversity: Geographic, gender, and career stage diversity
Presentation Quality: Track record of impactful presentations

Session Format

Presentation Structure

Each plenary session follows a structured format:

Introduction (5 minutes): Session chair introduces the topic and speaker

Main Presentation (35-40 minutes): In-depth coverage of the topic

Question and Answer (15-20 minutes): Audience questions

Audience Interaction

Live Q&A: Questions from attendees in person
Online Questions: Questions submitted via conference app
Session Hashtag: Social media engagement using #AAIC2026

Satellite Symposia

Plenary sessions are complemented by industry-sponsored satellite symposia providing additional in-depth coverage of specific topics.

Scientific Sessions

Concurrent scientific sessions allow for more detailed presentations on specialized topics:

Poster Sessions: Interactive presentations from researchers
Oral Abstracts: Selected abstract presentations
Focused Workshops: Hands-on learning opportunities

Networking Opportunities

Poster Sessions: Network with presenting researchers
Social Events: Conference receptions and dinners
Exhibition Floor: Engage with companies and organizations

Impact on the Field

Research Direction

Plenary presentations at AAIC frequently influence research directions:

New Hypotheses: Presentations generate new research questions
Methodological Advances: New approaches are shared and adopted
Collaborative Opportunities: Connections formed during sessions lead to collaborations

Clinical Practice

Trial Results: Clinical trial data influences practice guidelines
Diagnostic Advances: New diagnostic approaches enter practice
Therapeutic Updates: Approved therapy guidance

Public Health

Media Coverage: Major findings receive media attention
Policy Influence: Research informs public health policy
Awareness: Conference raises Alzheimer's awareness

Alzheimer's Disease

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Alzheimer's Disease Pathophysiology](/mechanisms/alzheimers-pathophysiology)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)

Key Proteins and Pathways

[Amyloid-beta Protein](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
[TREM2 Protein](/proteins/trem2)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation)

Therapeutic Approaches

[Anti-Amyloid Therapies](/therapeutics/anti-amyloid-therapies)
[Leqembi](/therapeutics/leqembi)
[Donanemab](/therapeutics/donanemab)

[AAIC 2026 Conference](/events/aaic-2026)
[AAIC 2026 Company Presentations](/events/aaic-2026-company-presentations)
[AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
[AAIC 2026 Clinical Trials](/events/aaic-2026-clinical-trials)
[Conference Index](/events/conference-index)

External Resources

[AAIC 2026 Official Program](https://aaic.alz.org/program)[@aaic2026]
[AAIC Archive](https://aaic.alz.org/archives)[@aaic_archive]
[Alzheimer's Association](https://www.alz.org/)
[PubMed Search: Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+disease)

Key References

[AAIC 2026 Official Program (2026)](https://aaic.alz.org/program)

[AAIC Plenary Sessions Archive](https://aaic.alz.org/archives)

[Battaglia et al., Amyloid and tau interactions in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35642084/)

[Heneka et al., Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25998905/)

[Scheltens et al., Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27064282/)

[Jack et al., NIA-AA Research Framework (2018)](https://pubmed.ncbi.nlm.nih.gov/29653606/)

[Selkoe & Hardy, The amyloid hypothesis at 25 years (2019)](https://pubmed.ncbi.nlm.nih.gov/31074661/)

[Long & Holtzman, Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37047030/)

📖 View canonical wiki page →

Related Entities

events-aaic-2026-plenary-sessions

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-aaic-2026-plenary-sessions
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-de459f250a1f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-aaic-2026-plenary-sessions'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

29

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AAIC 2026 Plenary Sessions

Overview

Overview

Conference Context

Role of Plenary Sessions at AAIC

AAIC 2026 Scientific Themes

Plenary Session Schedule

Sunday, July 12, 2026 — Opening Plenary

Monday, July 13, 2026 — Featured Plenary

Tuesday, July 14, 2026 — Keynote Address

Wednesday, July 15, 2026 — Closing Plenary

Major Scientific Topics

Amyloid and Tau Biology

Amyloid Pathology

Tau Pathology

Neuroinflammation

Microglial Biology

Neuroimmune Interactions

Biomarkers

Fluid Biomarkers

Imaging Biomarkers

Therapeutic Translation

Approved Therapies

Pipeline Programs

Prevention Strategies

Primary Prevention

Secondary Prevention

Plenary Speaker Profiles

Expected Speakers

Speaker Selection

Session Format

Presentation Structure

Audience Interaction

Related Conference Activities

Satellite Symposia

Scientific Sessions

Networking Opportunities

Impact on the Field

Research Direction

Clinical Practice

Public Health

Related NeuroWiki Content

Alzheimer's Disease

Key Proteins and Pathways

Therapeutic Approaches

Related Conferences

External Resources

Key References

💬 Discussion